MX2016009529A - Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos. - Google Patents

Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.

Info

Publication number
MX2016009529A
MX2016009529A MX2016009529A MX2016009529A MX2016009529A MX 2016009529 A MX2016009529 A MX 2016009529A MX 2016009529 A MX2016009529 A MX 2016009529A MX 2016009529 A MX2016009529 A MX 2016009529A MX 2016009529 A MX2016009529 A MX 2016009529A
Authority
MX
Mexico
Prior art keywords
hybridosomes
processes
compositions
production
same
Prior art date
Application number
MX2016009529A
Other languages
English (en)
Inventor
De Beer Joel
Original Assignee
Anjarium Biosciences Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anjarium Biosciences Ag filed Critical Anjarium Biosciences Ag
Publication of MX2016009529A publication Critical patent/MX2016009529A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La presente invención proporciona un vehículo biocompatible híbrido (hibridosoma) que comprende elementos estructurales y bioactivos que se originan de al menos un módulo de liberación biocompatible (MLB) y al menos un módulo de encapsulación de fármacos modificado por ingeniería (MEFI) que comprende al menos un resto fusogénico ajustable. La invención proporciona además composiciones farmacéuticas que comprenden dichos hibridosomas, procesos para su fabricación, así como usos farmacéuticos y métodos farmacéuticos basados en los mismos.
MX2016009529A 2014-01-21 2015-01-20 Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos. MX2016009529A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461929559P 2014-01-21 2014-01-21
PCT/IB2015/050436 WO2015110957A2 (en) 2014-01-21 2015-01-20 Hybridosomes, compositions comprising the same, processes for their production and uses thereof

Publications (1)

Publication Number Publication Date
MX2016009529A true MX2016009529A (es) 2016-10-17

Family

ID=52434912

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009529A MX2016009529A (es) 2014-01-21 2015-01-20 Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.
MX2021000174A MX2021000174A (es) 2014-01-21 2016-07-21 Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000174A MX2021000174A (es) 2014-01-21 2016-07-21 Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.

Country Status (13)

Country Link
US (3) US10561610B2 (es)
EP (2) EP3791863A1 (es)
JP (3) JP6598786B2 (es)
KR (3) KR102507475B1 (es)
CN (2) CN112870163A (es)
AU (3) AU2015208837B2 (es)
CA (1) CA2936514C (es)
DK (1) DK3096741T3 (es)
EA (1) EA037503B1 (es)
ES (1) ES2821758T3 (es)
MX (2) MX2016009529A (es)
WO (1) WO2015110957A2 (es)
ZA (1) ZA201604831B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013070324A1 (en) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
WO2014210448A1 (en) 2013-06-27 2014-12-31 The Board Of Regents Of The University Of Texas System Compositions and methods relating to myomaker-induced muscle cell fusion
CA2936514C (en) 2014-01-21 2023-08-08 Joel DE BEER Hybridosomes, compositions comprising the same, processes for their production and uses thereof
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
US11073511B2 (en) * 2016-02-01 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Exosome-Total-Isolation-Chip (ExoTIC) device for isolation of exosome-based biomarkers
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
CN107362370B (zh) * 2016-05-13 2022-07-26 国家纳米科学中心 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法
WO2017201340A2 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding relaxin
CN106280533B (zh) * 2016-08-17 2018-03-09 赣南师范大学 一种近红外荧光染料及其合成方法和用于寄生虫荧光标记
EP3292861A1 (en) * 2016-09-13 2018-03-14 Centre National De La Recherche Scientifique (Cnrs) An in vitro method for obtaining a biohybrid vector
BR112019022016A2 (pt) * 2017-04-19 2020-05-12 Apa- Advanced Technologies Ltd. Lipossomas fusogênicos, composições, kits e uso dos mesmos no tratamento do câncer
CN107084956B (zh) * 2017-05-05 2021-03-23 曲阜师范大学 一种基于醇溶剂诱导银纳米簇荧光增强的尿液中碘离子检测方法
JP7395355B2 (ja) * 2017-05-08 2023-12-11 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド 膜融合を促進するための組成物およびその使用
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
EP3658125A4 (en) * 2017-07-28 2021-04-28 National University of Singapore BIOMOLECULAR COMPOSITES INCLUDING MODIFIED CELL PHANTOMS
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
WO2019051428A1 (en) * 2017-09-11 2019-03-14 The Regents Of The University Of California CAS9 ANTIBODY MEDIA ADMINISTRATION TO MAMMALIAN CELLS
WO2019066434A1 (ko) * 2017-09-30 2019-04-04 주식회사 엑소코바이오 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물
KR102008665B1 (ko) * 2017-09-30 2019-08-08 주식회사 엑소코바이오 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물
CN108287134B (zh) * 2017-12-28 2020-11-24 南京邮电大学 单颗粒生物探针及其等离子体生物存储器的构建方法
CA3091478A1 (en) * 2018-02-17 2019-08-22 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
WO2019195819A1 (en) * 2018-04-06 2019-10-10 North Carolina State University Cell assembly-mediated delivery of checkpoint inhibitors for cancer immunotherapy
WO2019210189A1 (en) * 2018-04-26 2019-10-31 University Of Louisville Research Foundation, Inc. Edible plant exosome-like nanovectors for vaccination
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
CN110437628B (zh) * 2018-05-04 2021-05-04 中国石油化工股份有限公司 一种改性剂母液和道路沥青及其合成方法
KR20210021473A (ko) * 2018-05-15 2021-02-26 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 푸소솜 조성물 및 그의 용도
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3813798A1 (en) * 2018-06-28 2021-05-05 AstraZeneca AB Exosome extracellular vesicles and methods of use
PL3864163T3 (pl) 2018-10-09 2024-05-20 The University Of British Columbia Kompozycje i układy zawierające pęcherzyki zdolne do transfekcji wolne od rozpuszczalników organicznych i detergentów oraz związane z nimi sposoby postępowania
JP2022505714A (ja) * 2018-10-24 2022-01-14 エイピーエイ－ アドバンスト・テクノロジーズ・リミテッド 腫瘍細胞の選択的イメージングのための融合性リポソーム
WO2020102485A1 (en) * 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
US20230068547A1 (en) 2018-11-14 2023-03-02 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
CN109620969B (zh) * 2019-01-30 2021-02-05 广东药科大学 一种针对耐药肿瘤细胞的靶向抗肿瘤药物体系及其构建方法
WO2021010586A1 (ko) * 2019-07-15 2021-01-21 (주)심플스틱 항노화를 위한 피부 리프팅용 화장료 조성물 및 이를 이용한 피부미용 방법
CA3150779A1 (en) * 2019-08-12 2021-02-18 Integrated Nanotherapeutics Inc. Lipids for delivery of charged material, formulations thereof and method for making same
JP2022545656A (ja) * 2019-08-16 2022-10-28 ザ チルドレンズ メディカル センター コーポレーション エクソソーム模倣物のラージスケール生成およびそれらの使用
CN112415081A (zh) * 2019-08-23 2021-02-26 四川大学 一种基于稳定同位素检测的无标记CRISPR-Cas9分析方法
KR102297995B1 (ko) * 2019-10-24 2021-09-02 포항공과대학교 산학협력단 개방 동공을 갖는 산화철 나노큐브, 이의 제조방법 및 이의 용도
CN111007170B (zh) * 2019-12-13 2021-06-29 中国农业科学院农产品加工研究所 骨肽干预治疗骨质疏松中的生物标志物、筛选方法及用途
EP3858332A1 (en) * 2020-01-31 2021-08-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bottom-up assembly of synthetic extracellular vesicles
US20230285297A1 (en) * 2020-01-31 2023-09-14 Modernatx, Inc. Methods of preparing lipid nanoparticles
WO2021186079A1 (en) * 2020-03-20 2021-09-23 Heidelberg University Colloidal carrier systems for transfer of agents to a desired site of action
WO2022023284A1 (en) 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof
CN112094809A (zh) * 2020-10-19 2020-12-18 军事科学院军事医学研究院环境医学与作业医学研究所 一种从血清或血浆中提取外泌体的方法
US11535869B2 (en) 2021-04-08 2022-12-27 Sana Biotechnology, Inc. CD8-specific antibody constructs and compositions thereof
AU2022259546A1 (en) 2021-04-14 2023-11-16 Anjarium Biosciences Ag Fc-derived polypeptides
CA3214655A1 (en) 2021-04-14 2022-10-20 Joel DE BEER Peptides, nanovesicles, and uses thereof for drug delivery
WO2022255851A1 (ko) * 2021-06-04 2022-12-08 기초과학연구원 나노소포체 반응기 및 이의 제조방법
EP4373506A1 (en) 2021-07-20 2024-05-29 AGS Therapeutics SAS Extracellular vesicles from microalgae, their preparation, and uses
WO2023027082A1 (ja) * 2021-08-23 2023-03-02 積水化学工業株式会社 ペプチド結合ハイブリッドリポソームエクソソーム、ペプチド結合エクソソーム、これらを含む組成物及びその形成方法
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
WO2023244084A1 (ko) * 2022-06-17 2023-12-21 주식회사 엠디뮨 양이온성 지질 및 핵산분자를 포함하는 세포유래 베지클 및 이의 제조방법
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
US11944604B1 (en) 2023-03-10 2024-04-02 King Saud University Nanoformulation of spriooxindole and methods for treating hepatocellular carcinoma

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552155A (en) * 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
DE60334618D1 (de) 2002-06-28 2010-12-02 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
JP2010516786A (ja) * 2007-01-26 2010-05-20 ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション，インコーポレーテッド ワクチンとしての使用のためのエキソソーム成分の改変
EP2326331A4 (en) 2008-08-18 2013-05-15 Merck Sharp & Dohme NOVEL LIPID NANOPARTICLES AND NEW COMPONENTS FOR NUCLEIC ACID ADMINISTRATION
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
KR100950713B1 (ko) 2009-07-15 2010-03-31 (주)블루앤 음이온 발생기를 구비한 엘이디 램프
EP2467357B1 (en) 2009-08-20 2016-03-30 Sirna Therapeutics, Inc. Novel cationic lipids with various head groups for oligonucleotide delivery
EP2485770A4 (en) 2009-10-08 2013-04-10 Merck Sharp & Dohme NEW CATIONIC LIPIDS WITH SHORT LIPID CHAINS FOR ADMINISTRATION OF OLIGONUCLEOTIDES
SG10201407996PA (en) 2009-12-23 2015-01-29 Novartis Ag Lipids, lipid compositions, and methods of using them
EP2526113B1 (en) 2010-01-22 2016-08-10 Sirna Therapeutics, Inc. Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
US20120315324A1 (en) * 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
JP5149921B2 (ja) * 2010-02-19 2013-02-20 学校法人君が淵学園 癌細胞増殖抑制性ハイブリッド型リポソーム製剤
EP2555753B1 (en) * 2010-04-07 2018-08-01 California Institute of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
EA023397B1 (ru) 2010-05-26 2016-05-31 Селекта Байосайенсиз, Инк. Комбинированные вакцины с синтетическими наноносителями
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
WO2012002760A2 (ko) * 2010-07-01 2012-01-05 포항공과대학교 산학협력단 세균유래 마이크로베시클을 이용한 암치료 및 암진단 방법
KR101130137B1 (ko) 2010-07-02 2012-03-28 연세대학교 산학협력단 발광다이오드 모듈
WO2012024621A2 (en) 2010-08-20 2012-02-23 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin
EP3144015B1 (en) 2010-09-20 2021-06-02 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
AU2011307277A1 (en) 2010-09-30 2013-03-07 Merck Sharp & Dohme Corp. Low molecular weight cationic lipids for oligonucleotide delivery
JP2013545727A (ja) 2010-10-21 2013-12-26 メルク・シャープ・アンド・ドーム・コーポレーション オリゴヌクレオチド送達用の新規低分子量カチオン性脂質
WO2012061259A2 (en) 2010-11-05 2012-05-10 Merck Sharp & Dohme Corp. Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
WO2013048734A1 (en) 2011-09-28 2013-04-04 Tufts Medical Center, Inc. Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes
US20140308304A1 (en) * 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
JP2013128452A (ja) * 2011-12-21 2013-07-04 Toshiba Corp 定量分析装置、定量分析方法、脂質膜小胞、及び試薬
US9687448B2 (en) 2012-12-07 2017-06-27 Alnylam Pharmaceuticals, Inc. Nucleic acid lipid particle formulations
BR112015018877A2 (pt) * 2013-02-07 2017-08-22 Externautics Spa Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
CA2936514C (en) 2014-01-21 2023-08-08 Joel DE BEER Hybridosomes, compositions comprising the same, processes for their production and uses thereof
WO2022023284A1 (en) 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof
AU2022259546A1 (en) 2021-04-14 2023-11-16 Anjarium Biosciences Ag Fc-derived polypeptides
CA3214655A1 (en) 2021-04-14 2022-10-20 Joel DE BEER Peptides, nanovesicles, and uses thereof for drug delivery
CA3214538A1 (en) 2021-04-20 2022-10-27 Joel DE BEER Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
WO2023135273A2 (en) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof

Also Published As

Publication number Publication date
US11484500B2 (en) 2022-11-01
EP3096741B1 (en) 2020-09-02
KR102396026B1 (ko) 2022-05-09
US11944706B2 (en) 2024-04-02
JP2019218349A (ja) 2019-12-26
JP7046872B2 (ja) 2022-04-04
DK3096741T3 (da) 2020-09-28
AU2020227129B2 (en) 2022-06-30
ZA201604831B (en) 2018-05-30
JP2022101548A (ja) 2022-07-06
US20200222324A1 (en) 2020-07-16
CA2936514C (en) 2023-08-08
CN112870163A (zh) 2021-06-01
KR20160110410A (ko) 2016-09-21
AU2022218603A1 (en) 2022-09-15
WO2015110957A3 (en) 2015-12-03
US20160354313A1 (en) 2016-12-08
WO2015110957A2 (en) 2015-07-30
EP3791863A1 (en) 2021-03-17
MX2021000174A (es) 2021-03-25
KR20230039752A (ko) 2023-03-21
US20230181467A1 (en) 2023-06-15
JP6598786B2 (ja) 2019-10-30
US10561610B2 (en) 2020-02-18
ES2821758T3 (es) 2021-04-27
KR102541164B1 (ko) 2023-06-08
EP3096741A2 (en) 2016-11-30
AU2015208837A1 (en) 2016-08-11
KR102507475B1 (ko) 2023-03-07
CA2936514A1 (en) 2015-07-30
JP2017502997A (ja) 2017-01-26
CN105934240A (zh) 2016-09-07
AU2020227129A1 (en) 2020-10-01
CN105934240B (zh) 2021-02-09
EA037503B1 (ru) 2021-04-05
EA201691448A1 (ru) 2016-12-30
KR20220061286A (ko) 2022-05-12
AU2015208837B2 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
MX2021000174A (es) Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.
SI3577110T1 (sl) 8-oksetan-3-IL-3,8-diazabiciklo(3.2.1)oktan-3-IL substituirane spojine kot zaviralci HIV-a
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
PH12020500329A1 (en) Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
MX2016012846A (es) Preparacion de microesferas de plga cargadas de peptido con caracteristicas de liberacion controlada.
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
EP3318282A4 (en) DRUG DELIVERY VECTOR, AND COMPOSITION CONTAINING THE SAME
MX2016008369A (es) Composicion farmaceutica que incluye palonosetron.
PH12016501841A1 (en) Immunosuppressant formulation
WO2013080217A3 (en) Crystalline forms of carbazitaxel and process for preparation thereof
HUE057593T2 (hu) Eljárás lényegében diasztereomeresen tiszta foszfor-diamidát oligomer elõállítására, az eljárással készített foszfor-diamidát oligomer és a foszfor-diamidát oligomert tartalmazó gyógyszerészeti készítmény
MX2020000738A (es) Composicion de suministro de farmaco.
MY197524A (en) System of multiple bags and method for the preparation of hemocomponents
MX2018006773A (es) Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
EP3679608A4 (en) TRIPLET-TRIPLET ANNIHILATION CONVERSION-ELEVATION SYSTEM, AND ASSOCIATED COMPOSITIONS AND METHODS FOR DRUG DELIVERY
MX2016017124A (es) Proceso para la preparacion de acidos 3-hidroxipicolinicos.
PH12016500847A1 (en) Multi-particulate drug delivery system
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
WO2015095659A3 (en) Indirubin solid dispersion composition
WO2014128728A3 (en) Solid forms of cabazitaxel and processes for preparation thereof
EP3368609A4 (en) MULTIFUNCTIONAL BIODEGRADABLE CARRIER FOR ACTIVE INJECTION
MX2018005134A (es) Formulacion de factor viii (fviii).